Should You Buy Hims Stock Today?

Stock Advisor's reported total average return is 914% versus 184% for the S&P 500 (as of April 2, 2026). Hims & Hers (NYSE: HIMS) is described as one of the most volatile stocks recently and was not included in Stock Advisor's current top-10 picks. The Motley Fool discloses it holds and recommends Hims & Hers; the video's presenter has no position but may receive affiliate compensation for subscriptions.

Analysis

HIMS’s recent moves look driven less by fundamentals than by a fragile unit-economics story with lumpy marketing spend and subscription churn; a 15–25% sustained jump in CAC would likely push payback periods past 12 months and flip current FCF inflection calls into funding needs within 6–12 months. That makes short-term price action highly sensitive to marketing cadence, promo windows and any headline around tele-prescribing regulations — all of which are binary catalysts that can move the stock 20–40% in days-weeks.

On the derivatives side, elevated IV + retail directional flow produces recurring gamma and short-squeeze dynamics; dealers will hedge gamma into the print/earnings windows, amplifying intra-day moves and compressing liquidity on the way down. This creates a tactical environment where option structures (put spreads, collaring) dominate risk-adjusted outcomes vs naked equity exposure.

For NVDA vs INTC, the second-order winners are substrate/packaging and specialty EDA vendors — not just the fab nodes. NVDA’s premium reflects durable secular demand for accelerated compute and a willingness to pay for integration, whereas Intel’s path back depends on multi-year capital intensity and foundry-share gains; expect divergence to widen on any supply tightness or beat/miss in AI cloud demand over 6–18 months.

Contrarian read: the market may be over-penalizing HIMS’s headline volatility and ignoring potential margin upside from deeper insurance partnerships and cross-sell (telehealth → chronic Rx bundles). That argues for asymmetric, capped-risk trades rather than outright directional bets; absent a clear CAC uptick or regulatory hit, downside is likely pronounced but not binary — skew favors option-protection buys rather than large naked shorts.

Key Decisions for Investors

• HIMS: Initiate a 3–6 month put spread sized to 1% portfolio risk — buy a 1x 5–10% OTM put and sell a 1x deeper OTM put to finance premium. Rationale: captures a 20–35% downside from CAC/regulatory shocks while limiting max loss to premium (target payoff 2.5–4x if HIMS falls >25%). Place while 30-day IV > 6-month IV to reduce cost; cut if stock recovers 15% from entry.
• HIMS/NVDA pair: Long NVDA equity or 9–12 month LEAP calls (size 1.5% portfolio) funded by a short HIMS equity position (size 1%). Trade the macro rotation: if AI-capex stays robust, expect NVDA to outperform HIMS by >15% in 3–9 months. Stop-loss: trim NVDA if NVDA gap down >20% on broad market sell-off; cover HIMS if it reports CAC payback improvement.
• Relative-value NVDA/INTC: Construct a 9–12 month diagonal: long NVDA calls (OTM) and sell INTC calls (near-the-money) to express AI premium capture while financing time premium. Target: 2:1 payoff if NVDA outperforms INTC by 15–30% over 6–12 months. Risk: NVDA hardware inventory correction or a surprise Intel win; cap exposure to 2% portfolio.
• Governance/catalyst monitoring: Set alerts for HIMS quarterly print, telehealth regulatory notices, and NVDA cloud-processor ordering cycles. If HIMS CAC payback shortens by >20% on guidance, convert put spread to smaller short position; if NVDA inventory indicators roll over (channel destocking signs), exit the NVDA/INTC spread within 30 days.